NASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis $3.06 +0.03 (+0.99%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Elicio Therapeutics Stock (NASDAQ:ELTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elicio Therapeutics alerts:Sign Up Key Stats Today's Range$3.01▼$3.0850-Day Range$2.76▼$14.8552-Week Range$2.66▼$16.00Volume135,038 shsAverage Volume349,394 shsMarket Capitalization$58.42 millionP/E RatioN/ADividend YieldN/APrice Target$19.75Consensus RatingModerate Buy Company Overview Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y. Read More Elicio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreELTX MarketRank™: Elicio Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 413th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingElicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialElicio Therapeutics has a consensus price target of $19.75, representing about 545.4% upside from its current price of $3.06.Amount of Analyst CoverageElicio Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Elicio Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Elicio Therapeutics are expected to decrease in the coming year, from ($2.08) to ($2.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -1.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 34.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Elicio Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.83% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 5.07.Change versus previous monthShort interest in Elicio Therapeutics has recently decreased by 6.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.04 News SentimentElicio Therapeutics has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Elicio Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ELTX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows2 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTX Stock News HeadlinesElicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal AdenocarcinomaAugust 10 at 6:16 PM | markets.businessinsider.comElicio Therapeutics Announces Opening of MSK-Led Phase 1 Neoadjuvant Study of ELI-002 7P in Resectable Pancreatic CancerAugust 10 at 8:30 AM | quiverquant.comQBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.August 12 at 1:00 AM | Golden Portfolio (Ad)Elicio Therapeutics, Inc. (NASDAQ:ELTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 4, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTXJuly 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTXJuly 7, 2026 | globenewswire.comElicio Therapeutics Announces Closing of $15 Million Registered Direct OfferingJuly 6, 2026 | globenewswire.comAnother blow for ELTX? Elicio raises fresh capital weeks after trial disappointmentJuly 2, 2026 | msn.comSee More Headlines ELTX Stock Analysis - Frequently Asked Questions How have ELTX shares performed this year? Elicio Therapeutics' stock was trading at $7.96 at the start of the year. Since then, ELTX stock has decreased by 61.6% and is now trading at $3.06. How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.16. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an IPO on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Elicio Therapeutics' top institutional shareholders include BlackRock Inc. (4.01%), Bank of New York Mellon Corp (0.08%) and Deutsche Bank AG (0.07%). View institutional ownership trends. How do I buy shares of Elicio Therapeutics? Shares of ELTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elicio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA). Company Calendar Last Earnings5/11/2026Today8/12/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 8 days, ELTX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ELTX CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear Founded2011Price Target and Rating Average Price Target for Elicio Therapeutics$19.75 High Price Target$27.00 Low Price Target$12.00 Potential Upside/Downside+545.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-2,748.16% Return on Assets-151.12% Debt Debt-to-Equity Ratio5.75 Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book34.00Miscellaneous Outstanding Shares19,090,000Free Float9,371,000Market Cap$58.42 million OptionableNot Optionable Beta1.30 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ELTX) was last updated on 8/12/2026 by MarketBeat.com Staff. From Our PartnersIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
